Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 257 entries
Sorted by: Best Match Show Resources per page
Low-molecular-weight heparin-associated multiple digital necrosis in a patient as a result of heparin-induced thrombocytopenia syndrome.

Northern clinics of Istanbul

Kabakas F, Ugurlar M, Ugurlar OY, Bicer Y.
PMID: 34585078
North Clin Istanb. 2020 Aug 31;8(4):402-404. doi: 10.14744/nci.2020.37531. eCollection 2021.

Heparin-induced thrombocytopenia syndrome (HITS) is a rare complication of low-molecular-weight heparin (LMWH). It is an autoimmune-mediated side effect of LMWH which is caused by platelet-activating antibodies that recognize platelet factor-4/ heparin complexes. Although HITS often leads to thrombosis in...

Cite
Kabakas F, Ugurlar M, Ugurlar OY, et al. Low-molecular-weight heparin-associated multiple digital necrosis in a patient as a result of heparin-induced thrombocytopenia syndrome. North Clin Istanb. 2020;8(4):402-404doi: 10.14744/nci.2020.37531.
Kabakas, F., Ugurlar, M., Ugurlar, O. Y., & Bicer, Y. (2021). Low-molecular-weight heparin-associated multiple digital necrosis in a patient as a result of heparin-induced thrombocytopenia syndrome. Northern clinics of Istanbul, 8(4), 402-404. https://doi.org/10.14744/nci.2020.37531
Kabakas, Fatih, et al. "Low-molecular-weight heparin-associated multiple digital necrosis in a patient as a result of heparin-induced thrombocytopenia syndrome." Northern clinics of Istanbul vol. 8,4 (2021): 402-404. doi: https://doi.org/10.14744/nci.2020.37531
Kabakas F, Ugurlar M, Ugurlar OY, Bicer Y. Low-molecular-weight heparin-associated multiple digital necrosis in a patient as a result of heparin-induced thrombocytopenia syndrome. North Clin Istanb. 2020 Aug 31;8(4):402-404. doi: 10.14744/nci.2020.37531. eCollection 2021. PMID: 34585078; PMCID: PMC8430349.
Copy Download .nbib Format: NLM
European stroke organization interim expert opinion on cerebral venous thrombosis occurring after SARS-CoV-2 vaccination.

European stroke journal

Ferro JM, de Sousa DA, Coutinho JM, Martinelli I, Correnti R, Miller RJ.
PMID: 34746428
Eur Stroke J. 2021 Sep;6(3):CXVI-CXXI. doi: 10.1177/23969873211030842. Epub 2021 Jul 20.

Severe cases of cerebral venous thrombosis (CVT) with thrombocytopenia and anti-platelet factor 4 (PF4) antibodies occurring after adenoviral vector anti-SARS-CoV-2 vaccines have been recently reported. We aim to present a guidance document on the diagnosis and treatment of patients...

Cite
Ferro JM, de Sousa DA, Coutinho JM, et al. European stroke organization interim expert opinion on cerebral venous thrombosis occurring after SARS-CoV-2 vaccination. Eur Stroke J. 2021;6(3):CXVI-CXXIdoi: 10.1177/23969873211030842.
Ferro, J. M., de Sousa, D. A., Coutinho, J. M., Martinelli, I., Correnti, R., & Miller, R. J. (2021). European stroke organization interim expert opinion on cerebral venous thrombosis occurring after SARS-CoV-2 vaccination. European stroke journal, 6(3), CXVI-CXXI. https://doi.org/10.1177/23969873211030842
Ferro, José M, et al. "European stroke organization interim expert opinion on cerebral venous thrombosis occurring after SARS-CoV-2 vaccination." European stroke journal vol. 6,3 (2021): CXVI-CXXI. doi: https://doi.org/10.1177/23969873211030842
Ferro JM, de Sousa DA, Coutinho JM, Martinelli I, Correnti R, Miller RJ. European stroke organization interim expert opinion on cerebral venous thrombosis occurring after SARS-CoV-2 vaccination. Eur Stroke J. 2021 Sep;6(3):CXVI-CXXI. doi: 10.1177/23969873211030842. Epub 2021 Jul 20. PMID: 34746428; PMCID: PMC8564159.
Copy Download .nbib Format: NLM
Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines.

Vaccines

Rijkers GT, Weterings N, Obregon-Henao A, Lepolder M, Dutt TS, van Overveld FJ, Henao-Tamayo M.
PMID: 34451973
Vaccines (Basel). 2021 Aug 03;9(8). doi: 10.3390/vaccines9080848.

Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes Coronavirus Disease 2019 (COVID-19), which has reached pandemic proportions. A number of effective vaccines have been produced, including mRNA vaccines and viral vector vaccines, which are now being implemented...

Cite
Rijkers GT, Weterings N, Obregon-Henao A, et al. Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Vaccines (Basel). 2021;9(8)doi: 10.3390/vaccines9080848.
Rijkers, G. T., Weterings, N., Obregon-Henao, A., Lepolder, M., Dutt, T. S., van Overveld, F. J., & Henao-Tamayo, M. (2021). Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Vaccines, 9(8), . https://doi.org/10.3390/vaccines9080848
Rijkers, Ger T, et al. "Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines." Vaccines vol. 9,8 (2021). doi: https://doi.org/10.3390/vaccines9080848
Rijkers GT, Weterings N, Obregon-Henao A, Lepolder M, Dutt TS, van Overveld FJ, Henao-Tamayo M. Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Vaccines (Basel). 2021 Aug 03;9(8). doi: 10.3390/vaccines9080848. PMID: 34451973; PMCID: PMC8402319.
Copy Download .nbib Format: NLM
SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia.

Thrombosis research

Liu Y, Shao Z, Wang H.
PMID: 34894531
Thromb Res. 2021 Dec 06;209:75-79. doi: 10.1016/j.thromres.2021.12.002. Epub 2021 Dec 06.

SARS-CoV-2 vaccines have been carefully developed and significantly alleviate the global pandemic. However, a rare but severe complication after vaccination of adenoviral vector vaccines has attracted worldwide attention. It is characterized by thrombosis at unusual sites (often cerebral or...

Cite
Liu Y, Shao Z, Wang H. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. Thromb Res. 2021;209:75-79doi: 10.1016/j.thromres.2021.12.002.
Liu, Y., Shao, Z., & Wang, H. (2021). SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. Thrombosis research, 20975-79. https://doi.org/10.1016/j.thromres.2021.12.002
Liu, Yumei, et al. "SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia." Thrombosis research vol. 209 (2021): 75-79. doi: https://doi.org/10.1016/j.thromres.2021.12.002
Liu Y, Shao Z, Wang H. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. Thromb Res. 2021 Dec 06;209:75-79. doi: 10.1016/j.thromres.2021.12.002. Epub 2021 Dec 06. PMID: 34894531; PMCID: PMC8647389.
Copy Download .nbib Format: NLM
SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia.

Thrombosis research

Liu Y, Shao Z, Wang H.
PMID: 34894531
Thromb Res. 2021 Dec 06;209:75-79. doi: 10.1016/j.thromres.2021.12.002. Epub 2021 Dec 06.

SARS-CoV-2 vaccines have been carefully developed and significantly alleviate the global pandemic. However, a rare but severe complication after vaccination of adenoviral vector vaccines has attracted worldwide attention. It is characterized by thrombosis at unusual sites (often cerebral or...

Cite
Liu Y, Shao Z, Wang H. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. Thromb Res. 2021;209:75-79doi: 10.1016/j.thromres.2021.12.002.
Liu, Y., Shao, Z., & Wang, H. (2021). SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. Thrombosis research, 20975-79. https://doi.org/10.1016/j.thromres.2021.12.002
Liu, Yumei, et al. "SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia." Thrombosis research vol. 209 (2021): 75-79. doi: https://doi.org/10.1016/j.thromres.2021.12.002
Liu Y, Shao Z, Wang H. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. Thromb Res. 2021 Dec 06;209:75-79. doi: 10.1016/j.thromres.2021.12.002. Epub 2021 Dec 06. PMID: 34894531; PMCID: PMC8647389.
Copy Download .nbib Format: NLM
Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia.

Journal of clinical medicine

Tardy B, Lecompte T, Mullier F, Vayne C, Pouplard C.
PMID: 32344682
J Clin Med. 2020 Apr 24;9(4). doi: 10.3390/jcm9041226.

Heparin-induced thrombocytopenia (HIT) is a prothrombotic immune drug reaction caused by platelet-activating antibodies that in most instances recognize platelet factor 4 (PF4)/polyanion complexes. Platelet activation assays (i.e., functional assays) are more specific than immunoassays, since they are able to...

Cite
Tardy B, Lecompte T, Mullier F, et al. Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia. J Clin Med. 2020;9(4)doi: 10.3390/jcm9041226.
Tardy, B., Lecompte, T., Mullier, F., Vayne, C., & Pouplard, C. (2020). Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia. Journal of clinical medicine, 9(4), . https://doi.org/10.3390/jcm9041226
Tardy, Brigitte, et al. "Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia." Journal of clinical medicine vol. 9,4 (2020). doi: https://doi.org/10.3390/jcm9041226
Tardy B, Lecompte T, Mullier F, Vayne C, Pouplard C. Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia. J Clin Med. 2020 Apr 24;9(4). doi: 10.3390/jcm9041226. PMID: 32344682; PMCID: PMC7230370.
Copy Download .nbib Format: NLM
Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies and D-dimer elevation in Thai people After ChAdOx1 nCoV-19 vaccination.

Research and practice in thrombosis and haemostasis

Uaprasert N, Watanaboonyongcharoen P, Vichitratchaneekorn R, Trithiphen S, Akkawat B, Sukperm A, Tongbai T, Jantarabenjakul W, Paitoonpong L, Rojnuckarin P.
PMID: 34568726
Res Pract Thromb Haemost. 2021 Sep 18;5(6):e12580. doi: 10.1002/rth2.12580. eCollection 2021 Aug.

BACKGROUND: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare distinctive syndrome characterized by unusual site thrombosis accompanied by thrombocytopenia after ChAdOx1 nCoV-19 vaccination. Platelet-activating anti-platelet factor 4-dependent antibodies (anti-PF4 Abs) were detected in most cases of VITT. To date,...

Cite
Uaprasert N, Watanaboonyongcharoen P, Vichitratchaneekorn R, et al. Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies and D-dimer elevation in Thai people After ChAdOx1 nCoV-19 vaccination. Res Pract Thromb Haemost. 2021;5(6):e12580doi: 10.1002/rth2.12580.
Uaprasert, N., Watanaboonyongcharoen, P., Vichitratchaneekorn, R., Trithiphen, S., Akkawat, B., Sukperm, A., Tongbai, T., Jantarabenjakul, W., Paitoonpong, L., & Rojnuckarin, P. (2021). Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies and D-dimer elevation in Thai people After ChAdOx1 nCoV-19 vaccination. Research and practice in thrombosis and haemostasis, 5(6), e12580. https://doi.org/10.1002/rth2.12580
Uaprasert, Noppacharn, et al. "Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies and D-dimer elevation in Thai people After ChAdOx1 nCoV-19 vaccination." Research and practice in thrombosis and haemostasis vol. 5,6 (2021): e12580. doi: https://doi.org/10.1002/rth2.12580
Uaprasert N, Watanaboonyongcharoen P, Vichitratchaneekorn R, Trithiphen S, Akkawat B, Sukperm A, Tongbai T, Jantarabenjakul W, Paitoonpong L, Rojnuckarin P. Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies and D-dimer elevation in Thai people After ChAdOx1 nCoV-19 vaccination. Res Pract Thromb Haemost. 2021 Sep 18;5(6):e12580. doi: 10.1002/rth2.12580. eCollection 2021 Aug. PMID: 34568726; PMCID: PMC8449289.
Copy Download .nbib Format: NLM
Prevalence of anti-platelet factor 4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais.

Research and practice in thrombosis and haemostasis

Noikongdee P, Police P, Phojanasenee T, Chantrathammachart P, Niparuck P, Puavilai T, Phuphuakrat A, Angchaisuksiri P, Boonyawat K.
PMID: 34667921
Res Pract Thromb Haemost. 2021 Oct 11;5(7):e12600. doi: 10.1002/rth2.12600. eCollection 2021 Oct.

INTRODUCTION: Vaccine-induced thrombotic thrombocytopenia (VITT) has been reported after vaccination with the adenoviral vector coronavirus disease 2019 (COVID-19) vaccine ChAdOx1 nCoV-19 in European countries. To date, two cases of VITT have been reported in Thais after COVID-19 vaccination. We...

Cite
Noikongdee P, Police P, Phojanasenee T, et al. Prevalence of anti-platelet factor 4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais. Res Pract Thromb Haemost. 2021;5(7):e12600doi: 10.1002/rth2.12600.
Noikongdee, P., Police, P., Phojanasenee, T., Chantrathammachart, P., Niparuck, P., Puavilai, T., Phuphuakrat, A., Angchaisuksiri, P., & Boonyawat, K. (2021). Prevalence of anti-platelet factor 4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais. Research and practice in thrombosis and haemostasis, 5(7), e12600. https://doi.org/10.1002/rth2.12600
Noikongdee, Phichchapha, et al. "Prevalence of anti-platelet factor 4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais." Research and practice in thrombosis and haemostasis vol. 5,7 (2021): e12600. doi: https://doi.org/10.1002/rth2.12600
Noikongdee P, Police P, Phojanasenee T, Chantrathammachart P, Niparuck P, Puavilai T, Phuphuakrat A, Angchaisuksiri P, Boonyawat K. Prevalence of anti-platelet factor 4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais. Res Pract Thromb Haemost. 2021 Oct 11;5(7):e12600. doi: 10.1002/rth2.12600. eCollection 2021 Oct. PMID: 34667921; PMCID: PMC8505225.
Copy Download .nbib Format: NLM
Vaccine-induced immune thrombotic thrombocytopenia.

The Lancet. Haematology

Klok FA, Pai M, Huisman MV, Makris M.
PMID: 34774202
Lancet Haematol. 2021 Nov 11; doi: 10.1016/S2352-3026(21)00306-9. Epub 2021 Nov 11.

In response to the COVID-19 pandemic, vaccines for SARS-CoV-2 were developed, tested, and introduced at a remarkable speed. Although the vaccine introduction had a major impact on the evolution of COVID-19, some potential rare side-effects of the vaccines were...

Cite
Klok FA, Pai M, Huisman MV, et al. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol. 2021;doi: 10.1016/S2352-3026(21)00306-9.
Klok, F. A., Pai, M., Huisman, M. V., & Makris, M. (2021). Vaccine-induced immune thrombotic thrombocytopenia. The Lancet. Haematology, . https://doi.org/10.1016/S2352-3026(21)00306-9
Klok, Frederikus A, et al. "Vaccine-induced immune thrombotic thrombocytopenia." The Lancet. Haematology vol. (2021). doi: https://doi.org/10.1016/S2352-3026(21)00306-9
Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol. 2021 Nov 11; doi: 10.1016/S2352-3026(21)00306-9. Epub 2021 Nov 11. PMID: 34774202; PMCID: PMC8585488.
Copy Download .nbib Format: NLM
Intracerebral Hemorrhage and Thrombocytopenia After AstraZeneca COVID-19 Vaccine: Clinical and Diagnostic Challenges of Vaccine-Induced Thrombotic Thrombocytopenia.

Cureus

Wilting FNH, Kotsopoulos AMM, Platteel ACM, van Oers JAH.
PMID: 34646685
Cureus. 2021 Sep 01;13(9):e17637. doi: 10.7759/cureus.17637. eCollection 2021 Sep.

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a prothrombotic disorder, which has been described as a rare adverse effect of the adenoviral-vectored coronavirus disease 2019 (COVID-19) vaccines. The diagnosis is confirmed by the detection of anti-platelet factor 4 (PF4) antibodies...

Cite
Wilting FNH, Kotsopoulos AMM, Platteel ACM, et al. Intracerebral Hemorrhage and Thrombocytopenia After AstraZeneca COVID-19 Vaccine: Clinical and Diagnostic Challenges of Vaccine-Induced Thrombotic Thrombocytopenia. Cureus. 2021;13(9):e17637doi: 10.7759/cureus.17637.
Wilting, F. N. H., Kotsopoulos, A. M. M., Platteel, A. C. M., & van Oers, J. A. H. (2021). Intracerebral Hemorrhage and Thrombocytopenia After AstraZeneca COVID-19 Vaccine: Clinical and Diagnostic Challenges of Vaccine-Induced Thrombotic Thrombocytopenia. Cureus, 13(9), e17637. https://doi.org/10.7759/cureus.17637
Wilting, Floor N H, et al. "Intracerebral Hemorrhage and Thrombocytopenia After AstraZeneca COVID-19 Vaccine: Clinical and Diagnostic Challenges of Vaccine-Induced Thrombotic Thrombocytopenia." Cureus vol. 13,9 (2021): e17637. doi: https://doi.org/10.7759/cureus.17637
Wilting FNH, Kotsopoulos AMM, Platteel ACM, van Oers JAH. Intracerebral Hemorrhage and Thrombocytopenia After AstraZeneca COVID-19 Vaccine: Clinical and Diagnostic Challenges of Vaccine-Induced Thrombotic Thrombocytopenia. Cureus. 2021 Sep 01;13(9):e17637. doi: 10.7759/cureus.17637. eCollection 2021 Sep. PMID: 34646685; PMCID: PMC8486363.
Copy Download .nbib Format: NLM
Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia.

Thrombosis research

Thaler J, Jilma P, Samadi N, Roitner F, Mikušková E, Kudrnovsky-Moser S, Rettl J, Preiss R, Quehenberger P, Pabinger I, Knoebl P, Ay C.
PMID: 34624672
Thromb Res. 2021 Oct 04;207:126-130. doi: 10.1016/j.thromres.2021.09.017. Epub 2021 Oct 04.

BACKGROUND: Cases of ChAdOx1 nCoV-19 (AstraZeneca) vaccinated patients with thrombocytopenia, elevated D-dimer, and elevated platelet factor 4 (PF4) antibody levels with- and without thrombosis have been reported. No recommendations regarding the duration of anticoagulation have been made, because data...

Cite
Thaler J, Jilma P, Samadi N, et al. Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. Thromb Res. 2021;207:126-130doi: 10.1016/j.thromres.2021.09.017.
Thaler, J., Jilma, P., Samadi, N., Roitner, F., Mikušková, E., Kudrnovsky-Moser, S., Rettl, J., Preiss, R., Quehenberger, P., Pabinger, I., Knoebl, P., & Ay, C. (2021). Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. Thrombosis research, 207126-130. https://doi.org/10.1016/j.thromres.2021.09.017
Thaler, Johannes, et al. "Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia." Thrombosis research vol. 207 (2021): 126-130. doi: https://doi.org/10.1016/j.thromres.2021.09.017
Thaler J, Jilma P, Samadi N, Roitner F, Mikušková E, Kudrnovsky-Moser S, Rettl J, Preiss R, Quehenberger P, Pabinger I, Knoebl P, Ay C. Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. Thromb Res. 2021 Oct 04;207:126-130. doi: 10.1016/j.thromres.2021.09.017. Epub 2021 Oct 04. PMID: 34624672.
Copy Download .nbib Format: NLM
Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery: A Case Report.

Neurology

Walter U, Fuchs M, Grossmann A, Walter M, Thiele T, Storch A, Wittstock M.
PMID: 34312301
Neurology. 2021 Jul 26; doi: 10.1212/WNL.0000000000012576. Epub 2021 Jul 26.

OBJECTIVE: Venous thromboses and thrombocytopenia after vaccination with the adenovirus-vectored COVID-19 vaccine ChAdOx1 nCov-19 (AstraZeneca) have been linked to serum antibodies against platelet factor 4 (PF4)-polyanion complexes. We here report vaccine-induced isolated carotid arterial thrombosis.METHODS: Imaging and laboratory findings,...

Cite
Walter U, Fuchs M, Grossmann A, et al. Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery: A Case Report. Neurology. 2021;doi: 10.1212/WNL.0000000000012576.
Walter, U., Fuchs, M., Grossmann, A., Walter, M., Thiele, T., Storch, A., & Wittstock, M. (2021). Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery: A Case Report. Neurology, . https://doi.org/10.1212/WNL.0000000000012576
Walter, Uwe, et al. "Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery: A Case Report." Neurology vol. (2021). doi: https://doi.org/10.1212/WNL.0000000000012576
Walter U, Fuchs M, Grossmann A, Walter M, Thiele T, Storch A, Wittstock M. Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery: A Case Report. Neurology. 2021 Jul 26; doi: 10.1212/WNL.0000000000012576. Epub 2021 Jul 26. PMID: 34312301.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 257 entries